GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (BSP:P1RG34) » Definitions » Net Income (Discontinued Operations)

Perrigo Co (BSP:P1RG34) Net Income (Discontinued Operations) : R$-66 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Perrigo Co Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Perrigo Co's Net Income (Discontinued Operations) for the three months ended in Sep. 2024 was R$-19 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was R$-66 Mil.

Perrigo Co Net Income (Discontinued Operations) Historical Data

The historical data trend for Perrigo Co's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Net Income (Discontinued Operations) Chart

Perrigo Co Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.72 -1,063.92 350.60 -50.88 -40.67

Perrigo Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.93 -22.54 -10.46 -14.54 -18.83

Perrigo Co Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perrigo Co Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Perrigo Co's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Perrigo Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (BSP:P1RG34) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
ALVO PBH ALKS AMRX AMPH SUPN NDOI DVAX KNSA HROW ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB VTRS
Traded in Other Exchanges
PRGO:USA 0Y5E:UK PIG:Germany PIG:Germany
Address
The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74
Website
https://www.perrigo.com
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Perrigo Co Headlines

No Headlines